Verve Therapeutics - The best I've heard is that this company (a few years ago and still ongoing) began trying to create a permanent, one-off treatment for FH using gene technology:
The concept:
"Verve is developing a single-dose base-editing treatment for heterozygous familial hypercholesterolemia (HeFH)... the only in vivo base-editing candidate... specifically designed to permanently switch off the PCSK9 gene in the liver, to durably lower disease-driving low-density LDL-C. "
On HeFH:
"Verve is developing VERVE-102 to address this problem. VERVE-102 is a base editing medicine designed to switch off the PCSK9 gene in the liver in order to disrupt the liver’s production of the PCSK9 protein and lower blood levels of PCSK9 protein, and thereby durably lower LDL-C levels. "
For more information or to participate in clinical trials, vist Verve Therapeutics at www.vervetx.com.